keyword
MENU ▼
Read by QxMD icon Read
search

"febrile neutropenia"

keyword
https://www.readbyqxmd.com/read/29330406/adjuvant-role-of-septifast-to-improve-the-diagnosis-of-sepsis-in-a-large-cohort-of-hematological-patients
#1
Raffaella Greco, Maria Chiara Barbanti, Nicasio Mancini, Lara Crucitti, Chiara Oltolini, Alessandra Forcina, Francesca Lorentino, Luca Vago, Carlo Messina, Daniela Clerici, Mara Morelli, Fabio Giglio, Maria Teresa Lupo Stanghellini, Laura Infurnari, Matteo G Carrabba, Sarah Marktel, Andrea Assanelli, Paolo Scarpellini, Massimo Bernardi, Jacopo Peccatori, Consuelo Corti, Massimo Clementi, Fabio Ciceri
Febrile neutropenia and sepsis are common and life-threatening complications in hematological diseases. This study was performed retrospectively in 514 patients treated for febrile neutropenia at our institute, to investigate the clinical usefulness of a molecular tool, LightCycler® SeptiFast test (SF), to promptly recognize pathogens causing sepsis in hematological patients. We collected 1837 blood samples of 514 consecutive hematological patients. The time of processing is short. Overall, 757 microorganisms in 663 episodes were detected by molecular test and standard blood cultures (BC): 73...
January 12, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29330005/a-phase-i-study-of-irinotecan-capecitabine-xeloda-and-oxaliplatin-in-patients-with-advanced-colorectal-cancer
#2
Jean Maroun, Horia Marginean, Derek Jonker, Christine Cripps, Rakesh Goel, Timothy Asmis, Rachel Goodwin, Gabriela Chiritescu
BACKGROUND: The objective of the present phase I study was to define the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of irinotecan, capecitabine, and oxaliplatin given in combination (IXO regimen) to patients with previously untreated, unresectable advanced or metastatic colorectal cancer (CRC). PATIENTS AND METHODS: Patients received oxaliplatin followed by irinotecan as intravenous infusions on day 1, with oral capecitabine taken twice daily (BID) on days 2 to 15 of a 3-week cycle...
December 15, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29323859/calculated-decisions-mascc-risk-index-for-febrile-neutropenia
#3
Justin Taylor
No abstract text is available yet for this article.
January 2, 2018: Emergency Medicine Practice
https://www.readbyqxmd.com/read/29321348/influence-of-thiopurine-methyltransferase-gene-polymorphism-on-egyptian-children-with-acute-lymphoblastic-leukaemia
#4
Azza A G Tantawy, Fatma S E Ebeid, Amira A M Adly, Eman El-Ghoroury, Mai Mostafa
Thiopurine methyltransferase (TPMT) gene polymorphism regulates thiopurine therapeutic efficacy and toxicity. The aim of this study was to determine the influence of TPMT gene polymorphism in Egyptian children with acute lymphoblastic leukaemia (ALL). Sixty-four patients with ALL, T lineage (27%) and pre-B phenotype (73%), who were treated with BFM 90 or CCG 1991 standard risk protocol, and who also experiencedmyleosuppresion toxicity and required interruption and/ormodification of thiopurine chemotherapy were recruited over a year period...
December 2017: Journal of Genetics
https://www.readbyqxmd.com/read/29318740/risk-of-febrile-neutropenia-and-early-treatment-cessation-in-men-receiving-standard-and-dose-reduced-3-weekly-docetaxel-for-metastatic-castration-resistant-prostate-cancer
#5
Anis A Hamid, Kaspar Willson, Andrew D Vincent, Babak Tamjid, Margaret Lee, Alice Bergin, Chun Gan, Ainsley Campbell, Josephine Stewart, Carmel Pezaro, Ben Tran, Andrew J Weickhardt
BACKGROUND: Docetaxel is an effective therapy for metastatic castration-resistant prostate cancer (mCRPC); however, many patients experience febrile neutropenia (FN) and cease treatment early due to toxicity. It is not known whether lower dose (LD) q3-weekly docetaxel impacts toxicity or efficacy. METHODS: Multicenter retrospective study included 166 patients with mCRPC who received q3-weekly docetaxel between 2010 and 2015. Demographic, disease, chemotherapy (standard dose, SD>60 mg/m2 vs LD≤60 mg/m2 ) and toxicity data were collected...
January 10, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29317553/safety-profile-of-biosimilar-filgrastim-zarzio-zarxio-a-combined-analysis-of-phase-iii-studies
#6
Nadia Harbeck, Pere Gascón, Andriy Krendyukov, Nadja Hoebel, Sreekanth Gattu, Kimberly Blackwell
BACKGROUND: Evaluation of adverse events (AEs) in pivotal registration trials and ongoing postmarketing surveillance is important for all biologics, including biosimilars. A combined analysis of two pivotal registration studies was performed to strengthen evidence on safety for biosimilar filgrastim EP2006 in patients with breast cancer receiving myelosuppressive chemotherapy, a sensitive clinical setting to confirm biosimilarity of filgrastim. MATERIALS AND METHODS: Data were combined from two phase III studies of biosimilar filgrastim EP2006...
January 9, 2018: Oncologist
https://www.readbyqxmd.com/read/29316288/carboplatin-plus-pemetrexed-for-the-elderly-incurable-chemo-naive-nonsquamous-non-small-cell-lung-cancer-meta-analysis
#7
Masaru Ito, Nobuyuki Horita, Akimichi Nagashima, Takeshi Kaneko
AIM: In some developed countries, a proportion of nonsquamous non-small cell lung cancer (NSq NSCLC) patients are aged over 70 years when they are diagnosed. However, evidence of lung cancer chemotherapy usually comes from randomized controlled trials that only recruit younger patients with good performance status. In daily practice, less-toxic carboplatin + pemetrexed regimen is often used for elderly patients, although this regimen is not sufficiently supported by rigid evidence for elderly cases...
January 8, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29310696/methods-for-detecting-gemmata-spp-bacteremia-in-the-microbiology-laboratory
#8
Jacques-Robert Christen, Edwin Edmond, Michel Drancourt
OBJECTIVE: Gemmata bacteria are fastidious, Gram-negative and aerobic. The only representatives are Gemmata obscuriglobus and Gemmata massiliana. These Planctomycetes appear to be a part of human digestive tract microbiome, and G. massiliana has been isolated from water. Further specific detection in the blood of two patients with febrile neutropenia suggests that Gemmata bacteremia may remain under-documented. The objective of this study was to develop an effective protocol to document Gemmata spp...
January 8, 2018: BMC Research Notes
https://www.readbyqxmd.com/read/29310512/moxifloxacin-versus-levofloxacin-for-antibacterial-prophylaxis-in-acute-leukemia-patients
#9
Pauline Lee, Randall W Knoebel, Jennifer Pisano, Natasha N Pettit
Objective The primary endpoint of this study was to determine the incidence of febrile neutropenia among patients receiving either moxifloxacin or levofloxacin for antibacterial prophylaxis. Secondary endpoints were number of documented infections and in-hospital mortality in patients who develop febrile neutropenia. Methods A single-center retrospective cohort analysis at a large tertiary care academic medical center was conducted. This study included adult acute leukemia patients (age ≥18 years old) who received inpatient antibacterial prophylaxis (moxifloxacin or levofloxacin) from 1 July 2012 to 1 October 2014...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29304833/a-phase-i-study-of-selinexor-in-combination-with-high-dose-cytarabine-and-mitoxantrone-for-remission-induction-in-patients-with-acute-myeloid-leukemia
#10
Amy Y Wang, Howard Weiner, Margaret Green, Hua Chang, Noreen Fulton, Richard A Larson, Olatoyosi Odenike, Andrew S Artz, Michael R Bishop, Lucy A Godley, Michael J Thirman, Satyajit Kosuri, Jane E Churpek, Emily Curran, Kristen Pettit, Wendy Stock, Hongtao Liu
BACKGROUND: Novel therapies for patients with acute myeloid leukemia (AML) are imperative, particularly for those with high-risk features. Selinexor, an exportin 1 (XPO1/CRM1) inhibitor, has demonstrated anti-leukemia activity as a single agent, as well as in combination with anthracyclines and/or DNA-damaging agents. METHODS: We report the findings of a phase I dose escalation trial with cohort expansion in 20 patients with newly diagnosed or relapsed/refractory AML that combined selinexor with age-adjusted high-dose cytarabine and mitoxantrone (HiDAC/Mito)...
January 5, 2018: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29303041/changes-in-the-microbiological-epidemiology-of-febrile-neutropenia-in-autologous-stem-cell-transplant-recipients
#11
Rosa Rönkkö, Auni Juutilainen, Irma Koivula, Matti Vänskä, Tapio Nousiainen, Esa Jantunen, Sari Hämäläinen
BACKGROUND: The aim of the study was to explore the incidence, microbiological etiology and outcome of febrile neutropenia among adult hematological patients following autologous stem cell transplantation (ASCT). METHODS: The study population consisted of patients who received ASCT between 1 December 2006 and 30 November 2012. The epidemiology was compared to a retrospective series covering eleven previous years at the same institution. Non-Hodgkin lymphoma (NHL) patients, who had been identified as a risk group in the retrospective study, received ciprofloxacin prophylaxis from January 2008...
January 5, 2018: Infectious Diseases
https://www.readbyqxmd.com/read/29295612/the-effect-of-the-dexamethasone-cytarabine-and-cisplatin-dhap-regimen-on-stem-cell-mobilization-and-transplant-outcomes-of-patients-with-non-hodgkin-s-lymphoma-who-are-candidates-for-up-front-autologous-stem-cell-transplantation
#12
So Yeon Jeon, Ho-Young Yhim, Hee Sun Kim, Jeong-A Kim, Deok-Hwan Yang, Jae-Yong Kwak
Background/Aims: Data on dexamethasone, cytarabine, and cisplatin (DHAP) as a mobilization regimen, compared to high-dose cyclophosphamide (HDC), for up-front autologous stem cell transplantation (ASCT) in non-Hodgkin's lymphoma (NHL) is limited. Methods: Consecutive patients with aggressive NHL treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab-CHOP who underwent chemomobilization using HDC or DHAP plus granulocyte-colony stimulating factor (G-CSF) for up-front ASCT were enrolled from three institutions between 2004 and 2014...
January 8, 2018: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29290024/a-multi-institution-phase-ii-study-of-docetaxel-and-s-1-in-combination-with-trastuzumab-for-her2-positive-advanced-gastric-cancer-dash-study
#13
Shunsuke Kagawa, Atsushi Muraoka, Takeshi Kambara, Hiroshi Nakayama, Ryosuke Hamano, Norimitsu Tanaka, Kazuhiro Noma, Kohji Tanakaya, Hiroyuki Kishimoto, Kunitoshi Shigeyasu, Shinji Kuroda, Satoru Kikuchi, Kazuya Kuwada, Masahiko Nishizaki, Yasuhiro Shirakawa, Toshiyoshi Fujiwara
BACKGROUND: Trastuzumab when combined with fluoropyrimidine and cisplatin was proven to improve survival in patients with human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) in the ToGA study. The safety and efficacy of trastuzumab in combination with docetaxel and S-1 have not yet been evaluated. METHODS: This study was a multicenter, phase II study. Patients with chemotherapy-naïve HER2-positive advanced or metastatic GC were eligible...
December 30, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29288764/brief-report-tivantinib-in-combination-with-erlotinib-versus-erlotinib-alone-for-egfr-mutant-nsclc-an-exploratory-analysis-of-the-phase-3-marquee-study
#14
Giorgio V Scagliotti, Dale Shuster, Sergey Orlov, Joachim von Pawel, Frances A Shepherd, Jeffrey S Ross, Qiang Wang, Brian Schwartz, Wallace Akerley
INTRODUCTION: This exploratory subgroup analysis of the MARQUEE study evaluated the efficacy and safety of erlotinib plus tivantinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). METHODS: Patients with advanced, non-squamous, EGFR and mesenchymal-epithelial transition (MET) inhibitor-naive NSCLC, previously treated with 1 to 2 lines of systemic therapy, were randomized to oral erlotinib (150 mg once daily) plus tivantinib (360 mg twice daily) or to erlotinib plus placebo...
December 27, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29286572/predicting-bacterial-infections-among-pediatric-cancer-patients-with-febrile-neutropenia-external-validation-of-the-picnicc-model
#15
Rohit P Ojha, Peter H Asdahl, Ewout W Steyerberg, Henrik Schroeder
INTRODUCTION: The Predicting Infectious Complications in Neutropenic Children and Young People with Cancer (PICNICC) model was recently developed for antibiotic stewardship among pediatric cancer patients, but limited information is available about its clinical usefulness. We aimed to assess the performance of the PICNICC model for predicting microbiologically documented bacterial infections among pediatric cancer patients with febrile neutropenia. MATERIALS AND METHODS: We used data for febrile neutropenia episodes at a pediatric cancer center in Aarhus, Denmark between 2000 and 2016...
December 29, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29286213/risk-factors-for-invasive-fungal-infection-among-thai-oncologic-patients-with-febrile-neutropenia-and-cutaneous-presentation-a-5-year-retrospective-study-in-southern-thailand
#16
Kumpol Aiempanakit, Surarit Naorungroj, Kanokphorn Chiratikarnwong, Sauvarat Auepemkiate, Benjawan Apinantriyo
Background: Febrile neutropenia (FNP) is a condition defined by fever and neutropenia. There are current only limited data on related cutaneous manifestations. This study aimed to assess cutaneous lesions and their etiologies in a Thai group of FNP patients. Methods: A retrospective analysis was conducted on 43 non-transplant febrile neutropenic patients with concurrent cutaneous lesions, as determined by dermatopathologic studies at Songklanagarind Hospital in Thailand over a five-year period. Results: The mean age was 39 years (SD: 18...
December 29, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29285951/seifem-2017-from-real-life-to-an-agreement-on-the-use-of-granulocyte-transfusions-and-colony-stimulating-factors-for-prophylaxis-and-treatment-of-infectious-complications-in-patients-with-hematologic-malignant-disorders
#17
Alessandro Busca, Simone Cesaro, Luciana Teofili, Mario Delia, Chiara Cattaneo, Marianna Criscuolo, Francesco Marchesi, Nicola Stefano Fracchiolla, Caterina Giovanna Valentini, Francesca Farina, Roberta Di Blasi, Lucia Prezioso, Angelica Spolzino, Anna Candoni, Maria Ilaria Del Principe, Luisa Verga, Annamaria Nosari, Franco Aversa, Livio Pagano
The rapid spread of severe infections mainly due to resistant pathogens, justifies the search for therapies aiming to restore immune functions severely compromised in patients with hematologic malignancies. Areas covered: The present review summarizes the current knowledge on the role of granulocyte transfusions and colony-stimulating factors as treatment strategy for hematologic patients with serious infectious complications. In addition, a survey among 21 hematologic centers, to evaluate the clinical practice for the use of G-CSF originator and biosimilars was performed...
December 29, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/29285832/nimotuzumab-combined-with-concurrent-chemoradiotherapy-in-japanese-patients-with-esophageal-cancer-a-phase-i-study
#18
Ken Kato, Takashi Ura, Wasaburo Koizumi, Satoru Iwasa, Chikatoshi Katada, Mizutomo Azuma, Satoshi Ishikura, Yoshinori Nakao, Hiroshi Onuma, Kei Muro
Nimotuzumab is a humanized anti-epidermal growth factor receptor IgG1 monoclonal antibody. This phase I study assessed the tolerability, safety, efficacy, and PK of nimotuzumab in combination with chemoradiotherapy in Japanese patients with esophageal cancer. Patients with stage II, III, and IV esophageal cancer were enrolled. Patients were planned to receive nimotuzumab (level 1: 200 mg/week for 25 weeks; or level 2: 400 mg/week in the chemoradiation period, 400 mg biweekly in an additional chemotherapy period [8 weeks after the chemoradiation period] and a maintenance therapy period [after chemotherapy to 25 weeks]) combined with cisplatin (75 mg/m2 on day 1) and fluorouracil (1000 mg/m2 on days 1 to 4) in the chemoradiation and additional chemotherapy periods...
December 29, 2017: Cancer Science
https://www.readbyqxmd.com/read/29285558/meta-ethnography-of-experiences-of-early-discharge-with-a-focus-on-paediatric-febrile-neutropenia
#19
REVIEW
Jessica E Morgan, Jemma Cleminson, Lesley A Stewart, Robert S Phillips, Karl Atkin
PURPOSE (STATING THE MAIN PURPOSES AND RESEARCH QUESTION): Many children have no significant sequelae of febrile neutropenia. A systematic review of clinical studies demonstrated patients at low risk of septic complications can be safely treated as outpatients using oral antibiotics with low rates of treatment failure. Introducing earlier discharge may improve quality of life, reduce hospital acquired infection and reduce healthcare service pressures. However, the review raised concerns that this might not be acceptable to patients, families and healthcare professionals...
December 29, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29282494/incidence-of-neutropenia-and-use-of-granulocyte-colony-stimulating-factors-in-multiple-myeloma-is-current-clinical-practice-adequate
#20
REVIEW
Xavier Leleu, Francesca Gay, Anne Flament, Kim Allcott, Michel Delforge
Although immunomodulatory drugs, alkylating agents, corticosteroids, protease inhibitors, and therapeutic monoclonal antibodies improve multiple myeloma outcomes, treatment burden is still an issue. Neutropenia is a known complication of cytotoxic cancer therapy and is often associated with infections; it is an important consideration in myeloma given the fact that patients often have a weakened immune system. The risk of febrile neutropenia increases with severe and persisting neutropenia. Recombinant granulocyte colony-stimulating factors (G-CSFs) are commonly used to reduce the incidence, duration, and severity of febrile neutropenia...
December 27, 2017: Annals of Hematology
keyword
keyword
79323
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"